Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3018902 | 0.82 | HPGD (0.40) | USP2SMN1; SMN2HPGDEPHX2EPHX1 | |
| SCHEMBL13319381 | 0.81 | USP2 (0.49) | USP2SMN1; SMN2HPGDEPHX2TSHR | |
| SCHEMBL4189009 | 0.79 | USP2 (0.50) | USP2SMN1; SMN2HPGDEPHX2TSHR | |
| SCHEMBL3436829 | 0.78 | USP2 (0.56) | USP2SMN1; SMN2HPGDEPHX2TSHR | |
| SCHEMBL22532630 | 0.77 | USP2 (0.45) | USP2SMN1; SMN2HPGDEPHX2TSHR | |
| SCHEMBL78071 | 0.76 | USP2 (0.55) | USP2SMN1; SMN2HPGDEPHX2TSHR | |
| SCHEMBL13299664 | 0.76 | USP2 (0.44) | USP2SMN1; SMN2HPGDEPHX2TSHR | |
| SCHEMBL2477803 | 0.76 | TSHR (0.54) | TSHRALOX15ATMGPR119 | |
| SCHEMBL13232132 | 0.75 | USP2 (0.53) | USP2SMN1; SMN2HPGDEPHX2TSHR | |
| SCHEMBL18563357 | 0.75 | USP2 (0.53) | USP2SMN1; SMN2HPGDEPHX2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137305-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2142537-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008115973-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137305-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | AURKC, AURKA, AURKB | USP2 3421/4885SMN1; SMN2 2078/4885HPGD 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.